Skip to content

Cannabis: all studies

Page 59 of 289: studies 581 to 590 of 2,882, newest first. Back to the cannabis overview

Research

Association between formal thought disorder and cannabis use: a systematic review and meta-analysis

Schizophrenia September 29, 2022 Mathilde Argote, Guillaume Sescousse, Jérôme Brunelin et al. 7 citations

Formal thought disorder (FTD) is a multidimensional syndrome mainly occurring along the psychosis continuum. Cannabis use is known to increase symptoms of psychosis, particularly positive symptoms. However, the impact of cannabis use on FTD in individuals presenting symptoms along the psychosis continuum remains unclear. To address this knowledge gap, we conducted a meta-analysis examining the...

Shifts in therapeutic practices and decline of medicinal cannabis in Indian North-Eastern Frontier (1826–1925)

Journal of Cannabis Research September 28, 2022 Gita Bania

AbstractBackgroundThe emergence of colonial medicine in the North-Eastern Frontier witnessed different phases of consistent competition and resistance. Herbs such as cannabis provided native physicians with a coherent power to resist colonial medical intervention. Before British rule, cannabis assumed great significance in the socio-economic, cultural, and religious spheres. The colonizers’...

A Meta-Analysis of fMRI Studies of Youth Cannabis Use: Alterations in Executive Control, Social Cognition/Emotion Processing, and Reward Processing in Cannabis Using Youth

Brain Science September 23, 2022 C. Hammond, Aliyah Allick, Grace Park et al.

Background: Adolescent cannabis use (CU) is associated with adverse health outcomes and may be increasing in response to changing cannabis laws. Recent imaging studies have identified differences in brain activity between adult CU and controls that are more prominent in early onset users. Whether these differences are present in adolescent CU and relate to age/developmental stage, sex, or...

Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis

Psychological Medicine September 12, 2022 Rajiv Radhakrishnan, L. Pries, G. Erzin et al.

Abstract Background Empirical evidence suggests that people use cannabis to ameliorate anxiety and depressive symptoms, yet cannabis also acutely worsens psychosis and affective symptoms. However, the temporal relationship between cannabis use, anxiety and depressive symptoms and psychotic experiences (PE) in longitudinal studies is unclear. This may be informed by examination of mutually...

Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis

Translational Psychiatry September 6, 2022 Tabea Schoeler, Jason Ferris, Adam Winstock 48 citations

Cannabis, a widely used psychoactive substance, can trigger acute cannabis-associated psychotic symptoms (CAPS) in people who use cannabis (PWUC). To assess rates and correlates of CAPS requiring emergency medical treatment, we analyzed data from an international sample of PWUC (n = 233,475). We found that 0.47% (95%CI 0.42; 0.52) PWUC reported lifetime occurrence of CAPS, defined as the...

Association between ABCB1 rs2235048 Polymorphism and THC Pharmacokinetics and Subjective Effects following Smoked Cannabis in Young Adults

Brain Sciences September 3, 2022 Justin Matheson, Yollanda J. Zhang, Bruna Brands et al. 5 citations

Genetic influences on acute responses to psychoactive drugs may contribute to individual variability in addiction risk. ABCB1 is a human gene that encodes P-glycoprotein, an ATP-dependent efflux pump that may influence the pharmacokinetics of delta-9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. Using data from 48 young adults (aged 19–25 years) reporting 1–4 days...

DOI: 10.3390/brainsci12091189 (opens in new tab) Cannabis Delta-9-tetrahydrocannabinol Pharmacokinetics Genotype +6

Surface-based brain morphometry in schizophrenia vs. cannabis-induced psychosis: A controlled comparison.

Journal of Psychiatric Research September 1, 2022 Abhishek Ghosh, Simranjit Kaur, Raghav Shah et al.

BACKGROUND & AIM We examined group differences in cortical thickness and surface-parameters among age and handedness--matched persons with cannabis-induced psychosis (CIP), schizophrenia with heavy cannabis use (SZC), and healthy controls (HC). METHODS We recruited 31 men with SZC, 28 with CIP, and 30 with HC. We used the Psychiatric Research Interview for Substance and Mental Disorders to...

Association of cannabis potency with mental ill health and addiction: a systematic review.

The Lancet Psychiatry September 2022 Kat Petrilli, Shelan Ofori, Lindsey A. Hines et al.

Cannabis potency, defined as the concentration of Δ9-tetrahydrocannabinol (THC), has increased internationally, which could increase the risk of adverse health outcomes for cannabis users. We present, to our knowledge, the first systematic review of the association of cannabis potency with mental health and addiction (PROSPERO, CRD42021226447). We searched Embase, PsycINFO, and MEDLINE (from...

Cannabis use and attenuated positive and negative symptoms in youth at clinical high risk for psychosis.

Schizophrenia Research August 25, 2022 Olga Santesteban-Echarri, Lu Liu, Madeline Miller et al.

Cannabis use is more prevalent among youth at clinical high-risk (CHR) for psychosis than healthy controls (HC). There is mixed evidence as to whether cannabis use is associated with increased severity of attenuated psychotic symptoms (APS) or whether current cannabis use is associated with the transition to psychosis. This study aims to assess cannabis use differences between CHR youth and HC...

Chronic adolescent exposure to cannabis in mice leads to sex-biased changes in gene expression networks across brain regions

Neuropsychopharmacology August 22, 2022 Yanning Zuo, Attilio Iemolo, Patricia Montilla‐Perez et al. 24 citations

During adolescence, frequent and heavy cannabis use can lead to serious adverse health effects and cannabis use disorder (CUD). Rodent models of adolescent exposure to the main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), mimic the behavioral alterations observed in adolescent users. However, the underlying molecular mechanisms remain largely unknown. Here, we treated...